Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

110.85USD
16 Aug 2019
Change (% chg)

-- (--)
Prev Close
$110.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
586,362
52-wk High
$141.81
52-wk Low
$92.57

Latest Key Developments (Source: Significant Developments)

Alexion Pharmaceuticals Receives Marketing Authorization From EC For Ultomiris For Adults With PNH
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Alexion Pharmaceuticals Inc ::ULTOMIRIS® (RAVULIZUMAB) RECEIVES MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).ALEXION PHARMACEUTICALS - EC APPROVAL BASED ON RESULTS FROM TWO PHASE 3 STUDIES.  Full Article

FDA Grants Approval Of Soliris, A Treatment For Neuromyelitis Optica Spectrum Disorder, To Alexion Pharmaceuticals
Thursday, 27 Jun 2019 

June 27 (Reuters) - FDA::FDA APPROVES FIRST TREATMENT FOR NEUROMYELITIS OPTICA SPECTRUM DISORDER, A RARE AUTOIMMUNE DISEASE OF THE CENTRAL NERVOUS SYSTEM.FDA SAYS GRANTED APPROVAL OF SOLIRIS TO ALEXION PHARMACEUTICALS.FDA SAYS SOLIRIS HAS A BOXED WARNING THAT LIFE-THREATENING AND FATAL MENINGOCOCCAL INFECTIONS HAVE OCCURRED IN PATIENTS TREATED WITH SOLIRIS.  Full Article

Alexion Says FDA Accepted sBLA For Ultomiris Under Priority Review
Thursday, 20 Jun 2019 

June 20 (Reuters) - Alexion Pharmaceuticals Inc ::U.S. FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR ULTOMIRIS® (RAVULIZUMAB-CWVZ) UNDER PRIORITY REVIEW FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS).ALEXION PHARMACEUTICALS INC - FDA SETS TARGET ACTION DATE OF OCTOBER 19, 2019.  Full Article

Alexion Pharma Reports Positive Extension Data From Late-Stage Study of Ultomiris In Patients With Paroxysmal Nocturnal Hemoglobinuria
Friday, 14 Jun 2019 

June 14 (Reuters) - Alexion Pharmaceuticals Inc ::POSITIVE PHASE 3 EXTENSION DATA FOR ULTOMIRIS® (RAVULIZUMAB) IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PRESENTED AT EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS.ALEXION PHARMACEUTICALS INC - ULTOMIRIS DEMONSTRATED CONSISTENT EFFICACY AND SAFETY THROUGH 52 WEEKS.ALEXION PHARMACEUTICALS - SUSTAINED EFFICACY OF ULTOMIRIS WAS OBSERVED ON CO-PRIMARY ENDPOINTS OF TRANSFUSION AVOIDANCE & NORMALIZATION OF LDH LEVELS.ALEXION PHARMACEUTICALS - MOST COMMON ADVERSE EVENTS OCCURRED LESS FREQUENTLY IN EXTENSION PHASE THAN DURING INITIAL TREATMENT PHASE FOR ULTOMIRIS.ALEXION PHARMACEUTICALS - SUSTAINED EFFICACY OF ULTOMIRIS WAS OBSERVED ON SECONDARY ENDPOINTS OF LDH LEVEL REDUCTION AND BREAKTHROUGH HEMOLYSIS.  Full Article

Zealand Pharma And Alexion Announce Collaboration
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Zealand Pharma A/S ::REG-ALEXION AND ZEALAND PHARMA ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP PEPTIDE THERAPIES FOR COMPLEMENT-MEDIATED DISEASES.ZEALAND PHARMA TO RECEIVE UPFRONT PAYMENT OF $25 MILLION AND EQUITY INVESTMENT OF $15 MILLION.ZEALAND PHARMA WITH POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT AND ROYALTY PAYMENTS.AGREEMENT PROVIDES POTENTIAL FOR DEVELOPMENT-RELATED MILESTONES OF UP TO $115 MILLION.AGREEMENT PROVIDES AS WELL AS UP TO $495 MILLION IN SALES-RELATED MILESTONES AND POTENTIAL FOR HIGH SINGLE- TO LOW DOUBLE-DIGIT ROYALTY PAYMENTS.  Full Article

Alexion And Affibody Announce Partnership To Co-Develop Anti-FcRn Affibody Molecule
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND AFFIBODY ANNOUNCE PARTNERSHIP TO CO-DEVELOP ANTI-FCRN AFFIBODY® MOLECULE.ALEXION PHARMACEUTICALS INC - AGREEMENT PROVIDES OPPORTUNITY TO EXPAND ALEXION'S CLINICAL-STAGE ANTI-FCRN PORTFOLIO WITH ABY-039.ALEXION - AFFIBODY TO RECEIVE $25 MILLION UPFRONT PAYMENT WITH POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT AND ROYALTY PAYMENTS.ALEXION - POTENTIAL FOR ADDITIONAL MILESTONE PAYMENTS OF UP TO $625 MILLION AND TIERED LOW DOUBLE-DIGIT ROYALTY PAYMENTS AS PART OF DEAL.ALEXION - CO WILL LEAD JOINT CLINICAL DEVELOPMENT OF ABY-039 AND COMMERCIALIZATION ACTIVITIES.ALEXION - AFFIBODY HAS OPTION TO CO-PROMOTE ABY-039 IN U.S. AND WILL LEAD CLINICAL DEVELOPMENT FOR AN UNDISCLOSED INDICATION.  Full Article

Alexion Opposes Claims Against Co Filed By Chugai Pharmaceutical
Friday, 16 Nov 2018 

Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::ALEXION - RESPONDING TO COMPLAINT FILED AGAINST CO BY CHUGAI PHARMACEUTICAL, CO TO OPPOSE CLAIMS & TO PROCEED WITH BUSINESS PLANS FOR ALXN1210.  Full Article

Temasek Holdings (Private) Ltd Dissolves Share Stake In Walt Disney, Amgen and Biogen
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Temasek Holdings (Private) Ltd::TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN WALT DISNEY CO - SEC FILING.TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN AMGEN INC.TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN BIOGEN INC.TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN ALEXION PHARMACEUTICALS INC BY 18.5 PERCENT TO 1.2 MILLION SHARES.TEMASEK HOLDINGS (PRIVATE) LTD REPORTS SHARE STAKE OF 4.5 MILLION SHARES IN FARFETCH LTD.TEMASEK HOLDINGS (PRIVATE) LTD - CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2018.  Full Article

Alexion Q3 NON-GAAP Earnings Per Share $2.02
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION REPORTS THIRD QUARTER 2018 RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $2.02.Q3 GAAP EARNINGS PER SHARE $1.47.Q3 REVENUE $1.027 BILLION VERSUS I/B/E/S VIEW $1.02 BILLION.Q3 EARNINGS PER SHARE VIEW $1.74 -- THOMSON REUTERS I/B/E/S.ANNOUNCED AGREEMENT TO ACQUIRE SYNTIMMUNE AND COLLABORATION WITH DICERNA.UPDATED 2018 FULL-YEAR GUIDANCE.SEES 2018 REVENUE $4,020 MILLION TO $4,050 MILLION.ALEXION PHARMACEUTICALS - SEES 2018 ADJUSTED EARNINGS PER SHARE $7.45 TO $7.60.ALEXION PHARMACEUTICALS - EXPECTS TO INCUR ADDITIONAL RESTRUCTURING EXPENSES IN 2018 OF ABOUT $125 MILLION RELATED TO CO'S 2017 RESTRUCTURING ACTIVITIES.FY2018 EARNINGS PER SHARE VIEW $7.24, REVENUE VIEW $4.04 BILLION -- THOMSON REUTERS I/B/E/S.SEES FY18 GAAP EARNINGS PER SHARE BETWEEN LOSS OF $-0.08 TO PROFIT OF $0.26.  Full Article

Alexion And Dicerna Announce Collaboration To Discover And Develop RNAi Therapies For Complement-Mediated Diseases
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND DICERNA ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP RNAI THERAPIES FOR COMPLEMENT-MEDIATED DISEASES.DICERNA PHARMACEUTICALS INC - DICERNA TO RECEIVE UPFRONT PAYMENT OF $22 MILLION AND EQUITY INVESTMENT OF $15 MILLION.DICERNA PHARMACEUTICALS INC - DEAL HAS POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT AND ROYALTY PAYMENTS.DICERNA PHARMACEUTICALS - ALEXION MAKING A CONCURRENT $15 MILLION EQUITY INVESTMENT IN DICERNA AT A PREMIUM TO MARKET AS OF COLLABORATION EFFECTIVE DATE..DICERNA - COLLABORATION ALSO PROVIDES FOR POTENTIAL ADDITIONAL DEVELOPMENT AND APPROVAL-RELATED MILESTONE PAYMENTS OF UP TO $105 MILLION PER TARGET.DICERNA PHARMACEUTICALS INC - COLLABORATION ALSO PROVIDES FOR SALES MILESTONES AND MID-SINGLE TO LOW-DOUBLE DIGIT ROYALTIES ON FUTURE PRODUCT SALES..  Full Article

Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe

BOSTON Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones.